Karlson Elisa A. 4
4 · VALEANT PHARMACEUTICALS INTERNATIONAL · Filed Oct 20, 2010
Insider Transaction Report
Form 4
Karlson Elisa A.
EVP & Chief Administrative
Transactions
- Disposition to Issuer
Common Stock
2010-09-28−218,663→ 0 total - Disposition to Issuer
Incentive Stock Option (right to buy)
2010-09-28−25,856→ 0 totalExercise: $15.47Exp: 2018-05-20→ Common Stock (25,865 underlying) - Disposition to Issuer
Non-qualified Stock Option (right to buy)
2010-09-28−99,144→ 0 totalExercise: $15.47Exp: 2018-05-20→ Common Stock (99,144 underlying) - Disposition to Issuer
Non-qualified Stock Option (right to buy)
2010-09-28−55,970→ 0 totalExercise: $38.47Exp: 2017-03-03→ Common Stock (55,970 underlying)
Footnotes (3)
- [F1]8,978 restricted stock units disposed pursuant to merger agreement between issuer and Biovail Corporation, among others, in exchange for 25,119 Valeant Pharmaceuticals International, Inc. (formerly known as Biovail Corporation) restricted stock units, on the same terms and conditions. Remaining 209,685 restricted stock units disposed pursuant to merger agreement between issuer and, among others, Biovail Corporation in exchange for 373,428 shares of Valeant Pharmaceuticals International Inc. common stock. The fair market value of Valeant Pharmaceuticals International, Inc. on the effective date of the merger was $26.00 per share.
- [F2]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 349,722 shares of Valeant Pharmaceuticals International, Inc. common stock for $5.53 per share.
- [F3]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 156,590 shares of Valeant Pharmaceuticals International, Inc. common stock for $13.75 per share.